Rachel E. Factor
YOU?
Author Swipe
View article: Epigenetic markers of tumor progression in estrogen receptor–positive breast cancer patients with high nodal involvement
Epigenetic markers of tumor progression in estrogen receptor–positive breast cancer patients with high nodal involvement Open
Background Management of axillary lymph node (LN) disease in breast cancer (BC) is evolving, with declining use of axillary lymph node dissection. Consequently, prognostic information from nodal assessment is becoming limited. Molecular de…
View article: Erratum to “After neoadjuvant therapy, axillary sentinel lymph node frozen sections from breast cancer patients are accurately diagnosed using telepathology” [Journal of Pathology Informatics Volume 13, 2022, 100092]
Erratum to “After neoadjuvant therapy, axillary sentinel lymph node frozen sections from breast cancer patients are accurately diagnosed using telepathology” [Journal of Pathology Informatics Volume 13, 2022, 100092] Open
View article: Wide Margins are Still Relevant: A Case of a Well-Circumscribed Borderline Phyllodes Tumor With a Satellite Nodule in a Re-excision Margin
Wide Margins are Still Relevant: A Case of a Well-Circumscribed Borderline Phyllodes Tumor With a Satellite Nodule in a Re-excision Margin Open
View article: Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ
Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ Open
Importance Active monitoring for low-risk ductal carcinoma in situ (DCIS) of the breast has been proposed as an alternative to guideline-concordant care, but the safety of this approach is unknown. Objective To compare rates of invasive ca…
View article: A color‐based tumor segmentation method for clinical ex vivo breast tissue assessment utilizing a multi‐contrast brightfield imaging strategy
A color‐based tumor segmentation method for clinical ex vivo breast tissue assessment utilizing a multi‐contrast brightfield imaging strategy Open
We demonstrate an automated two‐step tumor segmentation method leveraging color information from brightfield images of fresh core needle biopsies of breast tissue. Three different color spaces (HSV, CIELAB, YCbCr) were explored for the seg…
View article: Single Cell Expression Analysis of Ductal Carcinoma in Situ Identifies Complex Genotypic-Phenotypic Relationships Altering Epithelial Composition
Single Cell Expression Analysis of Ductal Carcinoma in Situ Identifies Complex Genotypic-Phenotypic Relationships Altering Epithelial Composition Open
To identify mechanisms underlying the growth of ductal carcinoma in situ (DCIS) and properties that lead to progression to invasive cancer, we performed single-cell RNA-sequencing (scRNA-seq) on DCIS lesions and matched synchronous normal …
View article: A Non-Contrast Multi-Parametric MRI Biomarker for Assessment of MR-Guided Focused Ultrasound Thermal Therapies
A Non-Contrast Multi-Parametric MRI Biomarker for Assessment of MR-Guided Focused Ultrasound Thermal Therapies Open
Voxel-wise registration of MPMR data to histological outcomes facilitated supervised learning of an accurate non-contrast MR biomarker for MRgFUS ablations in a rabbit VX2 tumor model.
View article: A color-based tumor segmentation method for clinical ex vivo breast tissue assessment utilizing a multi-contrast brightfield imaging strategy
A color-based tumor segmentation method for clinical ex vivo breast tissue assessment utilizing a multi-contrast brightfield imaging strategy Open
We demonstrate an automated two-step tumor segmentation method leveraging color information from brightfield images of fresh core needle biopsies of breast tissue. Three different color spaces (HSV, CIELAB, YCbCr) were explored for the seg…
View article: Comparison of Diagnostic Sensitivity and Procedure-Related Pain of Concurrent Ultrasound-guided Fine-needle Aspiration and Core-needle Biopsy of Axillary Lymph Nodes in Patients with Suspected or Known Breast Cancer
Comparison of Diagnostic Sensitivity and Procedure-Related Pain of Concurrent Ultrasound-guided Fine-needle Aspiration and Core-needle Biopsy of Axillary Lymph Nodes in Patients with Suspected or Known Breast Cancer Open
Objective Conflicting data exist on the diagnostic sensitivity of core-needle biopsy (CNB) compared to fine-needle aspiration (FNA) in the evaluation of axillary lymph node metastasis from breast cancer. Our purpose was to evaluate the sen…
View article: Myeloid Sarcoma of the Breast: A Diagnostic Dilemma With Pathologic Correlation
Myeloid Sarcoma of the Breast: A Diagnostic Dilemma With Pathologic Correlation Open
Myeloid sarcoma (MS) is a rare extramedullary solid tumor arising most often in patients with current or subsequent acute myeloid leukemia (AML). Patients of all ages may present with involvement of the skin, lymph nodes, intestinal tract,…
View article: Table S3 from BRCA1 through Its E3 Ligase Activity Regulates the Transcription Factor Oct1 and Carbohydrate Metabolism
Table S3 from BRCA1 through Its E3 Ligase Activity Regulates the Transcription Factor Oct1 and Carbohydrate Metabolism Open
RNAseq analysis of dysregulated genes from Oct1-KO and control BRCA1-I26A MEFs.
View article: Table S3 from BRCA1 through Its E3 Ligase Activity Regulates the Transcription Factor Oct1 and Carbohydrate Metabolism
Table S3 from BRCA1 through Its E3 Ligase Activity Regulates the Transcription Factor Oct1 and Carbohydrate Metabolism Open
RNAseq analysis of dysregulated genes from Oct1-KO and control BRCA1-I26A MEFs.
View article: Figures S1-S13 from BRCA1 through Its E3 Ligase Activity Regulates the Transcription Factor Oct1 and Carbohydrate Metabolism
Figures S1-S13 from BRCA1 through Its E3 Ligase Activity Regulates the Transcription Factor Oct1 and Carbohydrate Metabolism Open
Supp. Figure S1 Differential metabolite levels in BRCA1 I26A compared to normal MEFs. Supp. Figure S2 Control immunofluorescence microscopy images using Oct1-deficient MEFs. Supp. Figure S3 Small increase in Oct1 proteins levels in MEFs wi…
View article: Supplementary Data Legends from BRCA1 through Its E3 Ligase Activity Regulates the Transcription Factor Oct1 and Carbohydrate Metabolism
Supplementary Data Legends from BRCA1 through Its E3 Ligase Activity Regulates the Transcription Factor Oct1 and Carbohydrate Metabolism Open
Legends for Supplementary Figures S1-S13, and Tables S1-S4
View article: Table S4 from BRCA1 through Its E3 Ligase Activity Regulates the Transcription Factor Oct1 and Carbohydrate Metabolism
Table S4 from BRCA1 through Its E3 Ligase Activity Regulates the Transcription Factor Oct1 and Carbohydrate Metabolism Open
Oct1 and BRCA1 staining in breast cancer tissues.
View article: Data from BRCA1 through Its E3 Ligase Activity Regulates the Transcription Factor Oct1 and Carbohydrate Metabolism
Data from BRCA1 through Its E3 Ligase Activity Regulates the Transcription Factor Oct1 and Carbohydrate Metabolism Open
The tumor suppressor BRCA1 regulates the DNA damage response (DDR) and other processes that remain incompletely defined. Among these, BRCA1 heterodimerizes with BARD1 to ubiquitylate targets via its N-terminal E3 ligase activity. Here, it …
View article: Table S1 from BRCA1 through Its E3 Ligase Activity Regulates the Transcription Factor Oct1 and Carbohydrate Metabolism
Table S1 from BRCA1 through Its E3 Ligase Activity Regulates the Transcription Factor Oct1 and Carbohydrate Metabolism Open
Original and normalized GC-MS metabolite readings from control and BRCA1-I26A mutant MEFs.
View article: Table S1 from BRCA1 through Its E3 Ligase Activity Regulates the Transcription Factor Oct1 and Carbohydrate Metabolism
Table S1 from BRCA1 through Its E3 Ligase Activity Regulates the Transcription Factor Oct1 and Carbohydrate Metabolism Open
Original and normalized GC-MS metabolite readings from control and BRCA1-I26A mutant MEFs.
View article: Table S2 from BRCA1 through Its E3 Ligase Activity Regulates the Transcription Factor Oct1 and Carbohydrate Metabolism
Table S2 from BRCA1 through Its E3 Ligase Activity Regulates the Transcription Factor Oct1 and Carbohydrate Metabolism Open
RNAseq gene expression changes in BRCA1-I26A mutant MEFs (Oct1 CRISPR vs control).
View article: Data from BRCA1 through Its E3 Ligase Activity Regulates the Transcription Factor Oct1 and Carbohydrate Metabolism
Data from BRCA1 through Its E3 Ligase Activity Regulates the Transcription Factor Oct1 and Carbohydrate Metabolism Open
The tumor suppressor BRCA1 regulates the DNA damage response (DDR) and other processes that remain incompletely defined. Among these, BRCA1 heterodimerizes with BARD1 to ubiquitylate targets via its N-terminal E3 ligase activity. Here, it …
View article: Figures S1-S13 from BRCA1 through Its E3 Ligase Activity Regulates the Transcription Factor Oct1 and Carbohydrate Metabolism
Figures S1-S13 from BRCA1 through Its E3 Ligase Activity Regulates the Transcription Factor Oct1 and Carbohydrate Metabolism Open
Supp. Figure S1 Differential metabolite levels in BRCA1 I26A compared to normal MEFs. Supp. Figure S2 Control immunofluorescence microscopy images using Oct1-deficient MEFs. Supp. Figure S3 Small increase in Oct1 proteins levels in MEFs wi…
View article: Table S2 from BRCA1 through Its E3 Ligase Activity Regulates the Transcription Factor Oct1 and Carbohydrate Metabolism
Table S2 from BRCA1 through Its E3 Ligase Activity Regulates the Transcription Factor Oct1 and Carbohydrate Metabolism Open
RNAseq gene expression changes in BRCA1-I26A mutant MEFs (Oct1 CRISPR vs control).
View article: Table S4 from BRCA1 through Its E3 Ligase Activity Regulates the Transcription Factor Oct1 and Carbohydrate Metabolism
Table S4 from BRCA1 through Its E3 Ligase Activity Regulates the Transcription Factor Oct1 and Carbohydrate Metabolism Open
Oct1 and BRCA1 staining in breast cancer tissues.
View article: Supplementary Data Legends from BRCA1 through Its E3 Ligase Activity Regulates the Transcription Factor Oct1 and Carbohydrate Metabolism
Supplementary Data Legends from BRCA1 through Its E3 Ligase Activity Regulates the Transcription Factor Oct1 and Carbohydrate Metabolism Open
Legends for Supplementary Figures S1-S13, and Tables S1-S4
View article: Supplemental Figure from Discordant Haplotype Sequencing Identifies Functional Variants at the 2q33 Breast Cancer Risk Locus
Supplemental Figure from Discordant Haplotype Sequencing Identifies Functional Variants at the 2q33 Breast Cancer Risk Locus Open
Supplemental Figure: Description of sample sets for the DNAseq and RNAseq experiments.
View article: Supplementary Data from A Multigene Assay Determines Risk of Recurrence in Patients with Triple-Negative Breast Cancer
Supplementary Data from A Multigene Assay Determines Risk of Recurrence in Patients with Triple-Negative Breast Cancer Open
Supplementary Tables 1 and 2 include MHCII Immune Activation Assay Probe Sequences and Patient Demographic Data and Disease Characteristics
View article: Supplemental Methods and Supplemental Table from Discordant Haplotype Sequencing Identifies Functional Variants at the 2q33 Breast Cancer Risk Locus
Supplemental Methods and Supplemental Table from Discordant Haplotype Sequencing Identifies Functional Variants at the 2q33 Breast Cancer Risk Locus Open
Equations to calculate sample size in a homozygous discordant design. Supplemental Table: Sample size requirements (n in each group)
View article: Supplemental Methods and Supplemental Table from Discordant Haplotype Sequencing Identifies Functional Variants at the 2q33 Breast Cancer Risk Locus
Supplemental Methods and Supplemental Table from Discordant Haplotype Sequencing Identifies Functional Variants at the 2q33 Breast Cancer Risk Locus Open
Equations to calculate sample size in a homozygous discordant design. Supplemental Table: Sample size requirements (n in each group)
View article: Supplementary Data from A Multigene Assay Determines Risk of Recurrence in Patients with Triple-Negative Breast Cancer
Supplementary Data from A Multigene Assay Determines Risk of Recurrence in Patients with Triple-Negative Breast Cancer Open
Supplemental Figures 1-7 include a graphical outline of the study, graphs depicting probe performance, correlations between MHCII and TIL scores, ROC statistics, and additional Kaplan Meier curves.
View article: Data from Discordant Haplotype Sequencing Identifies Functional Variants at the 2q33 Breast Cancer Risk Locus
Data from Discordant Haplotype Sequencing Identifies Functional Variants at the 2q33 Breast Cancer Risk Locus Open
The findings from genome-wide association studies hold enormous potential for novel insight into disease mechanisms. A major challenge in the field is to map these low-risk association signals to their underlying functional sequence varian…